FDA/CDC

FDA alerts doctors to stop administering compounded products


 

The Food and Drug Administration today alerted physicians to stop administering or providing drugs manufactured by Cantrell Drug, including opioid products and other drugs intended for sterile injection, because the company has failed to ensure quality and sterility in its compounding operations, which could seriously compromise patient safety.

Health care providers should check medical supplies and separate anything produced by Cantrell Drug, which can be identified by finding the company’s name on the label. The FDA also recommended that physicians seek alternative arrangements for medicines and that any patients who have any products made by Cantrell contact their physicians.

FDA icon
The FDA has sought legal action against Cantrell to halt its production and distribution operations. The FDA raised serious concerns after an inspection in June 2017 revealed unsanitary conditions and violations of current Good Manufacturing Practice. This led to a recall and cessation of production of all sterile products; however, Cantrell resumed production and distribution against FDA advice.

So far, the FDA is not aware of any illness or injuries caused by potentially contaminated products from Cantrell, but any that do arise should be reported to the FDA’s MedWatch program.

Read more about this alert in the FDA website.

Recommended Reading

CDC confirms first cases of locally transmitted Zika in continental U.S.
MDedge Dermatology
Statin use increases risk of herpes zoster
MDedge Dermatology
Strontium, ketamine target troublesome itch
MDedge Dermatology
FDA approves first specific treatment for giant cell arteritis
MDedge Dermatology
FDA asks drug maker to shelve Opana ER
MDedge Dermatology
Pain often persists despite biologic treatment in PsA
MDedge Dermatology
Diagnosing high-risk keratinocyte carcinomas in the dermatology clinic
MDedge Dermatology
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Dermatology
In close vote, advisory panel prefers Shingrix over Zostavax
MDedge Dermatology
Five pearls target wound healing
MDedge Dermatology